Home
ENVB
ENVB News

Latest Enveric Biosciences Inc. (ENVB) News on October 30, 2025

Enveric Biosciences Announces Reverse Stock Split

Business Wire

7 days ago

Enveric Biosciences Announces Reverse Stock Split

Market Exclusive

10 days ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance

Business Wire

14 days ago

Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance

AbbVie's Bretisilocin Hit With Enveric IP Claim

GuruFocus.com

14 days ago

AbbVie's Bretisilocin Hit With Enveric IP Claim

Investing.com

15 days ago

Enveric Biosciences hires Fish & Richardson to defend patent tied to AbbVie deal

Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

Business Wire

15 days ago

Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

Enveric Biosciences to Explore Digital Asset Treasury Opportunities

Business Wire

16 days ago

Enveric Biosciences to Explore Digital Asset Treasury Opportunities

Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials

Business Wire

a month ago

Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials

Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial

TipRanks

4 months ago

Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial

Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003

Business Wire

4 months ago

Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003

Business Wire

4 months ago

Enveric Biosciences Announces Participation in 2025 BIO International Convention

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

Business Wire

5 months ago

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

Business Wire

5 months ago

Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

Enveric Biosciences announces results from EB-003 trial

TipRanks

5 months ago

Enveric Biosciences announces results from EB-003 trial

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

Business Wire

5 months ago

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease

Business Wire

5 months ago

Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

Business Wire

6 months ago

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

Business Wire

7 months ago

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

Enveric Biosciences Participating in BIO-Europe Spring®

Business Wire

7 months ago

Enveric Biosciences Participating in BIO-Europe Spring®

Enveric Biosciences launches RFP solicitation process for PsyAI trademark

TipRanks

8 months ago

Enveric Biosciences launches RFP solicitation process for PsyAI trademark

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark

Business Wire

8 months ago

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark

Psychedelic: GH Research, Compass Pathways report earnings results

TipRanks

8 months ago

Psychedelic: GH Research, Compass Pathways report earnings results

Enveric Biosciences CEO Issues Letter to Shareholders

Business Wire

8 months ago

Enveric Biosciences CEO Issues Letter to Shareholders

Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent

Business Wire

8 months ago

Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent

Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease

Business Wire

9 months ago

Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease

Enveric Biosciences Announces Closing of $5 Million Public Offering

Business Wire

9 months ago

Enveric Biosciences Announces Closing of $5 Million Public Offering

Enveric Biosciences Prices $5 Million Public Offering; Shares Drop 40% in Premarket Trading

GuruFocus.com

9 months ago

Enveric Biosciences Prices $5 Million Public Offering; Shares Drop 40% in Premarket Trading

Enveric Biosciences Announces Pricing of $5 Million Public Offering

Business Wire

9 months ago

Enveric Biosciences Announces Pricing of $5 Million Public Offering

Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office

Business Wire

9 months ago

Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During "J.P. Morgan Week 2025"

Business Wire

10 months ago

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During "J.P. Morgan Week 2025"

Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds

Business Wire

a year ago

Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds

Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior

Business Wire

a year ago

Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior

Market Exclusive

a year ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results

Business Wire

a year ago

Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results

Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002

Business Wire

a year ago

Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002

Enveric Biosciences Announces Broad Range of Patent Issuances

Business Wire

a year ago

Enveric Biosciences Announces Broad Range of Patent Issuances

Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003

Business Wire

a year ago

Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003

Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop

Business Wire

a year ago

Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop

Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit

Business Wire

a year ago

Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit

Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Business Wire

a year ago

Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries’ License for Treatment of Radiation Dermatitis and Other Conditions

Business Wire

a year ago

Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries’ License for Treatment of Radiation Dermatitis and Other Conditions

Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results

Business Wire

a year ago

Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results

Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally

Business Wire

a year ago

Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally

Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement

Business Wire

a year ago

Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement

Enveric Biosciences Announces Patent Granted for Drug Candidate

Business Wire

a year ago

Enveric Biosciences Announces Patent Granted for Drug Candidate

Is Enveric Biosciences, Inc. (NASDAQ:ENVB) Trading At A 36% Discount?

Simply Wall St.

a year ago

Is Enveric Biosciences, Inc. (NASDAQ:ENVB) Trading At A 36% Discount?

GlobeNewswire

a year ago

Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)

Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate

Business Wire

a year ago

Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate

Journal-News, Hamilton, Ohio

a year ago

Retiring ODW executive to be first inductee in Hamilton Business Hall of Fame

Cat-sitting startup Meowtel clawed its way to profitability despite trouble raising from dog-focused VCs

TechCrunch

a year ago

Cat-sitting startup Meowtel clawed its way to profitability despite trouble raising from dog-focused VCs

Once-in-a-Generation Investment Opportunity: Why You Should Buy Carnival Stock Now

Motley Fool

a year ago

Once-in-a-Generation Investment Opportunity: Why You Should Buy Carnival Stock Now

Italian energy company targets Britain for fleet of 20 mini-nukes

The Telegraph

a year ago

Italian energy company targets Britain for fleet of 20 mini-nukes

It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend

Simply Wall St.

a year ago

It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend

Saudis Said to Hand About 60% of Aramco Offer to Foreigners

Bloomberg

a year ago

Saudis Said to Hand About 60% of Aramco Offer to Foreigners

Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?

Simply Wall St.

a year ago

Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?

Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks

Simply Wall St.

a year ago

Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks

Enveric Biosciences to Participate in BIO International Convention 2024

Business Wire

a year ago

Enveric Biosciences to Participate in BIO International Convention 2024

Market Exclusive

a year ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results

Business Wire

a year ago

Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results

Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders

Business Wire

a year ago

Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders

Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids

Business Wire

a year ago

Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023

Business Wire

2 years ago

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease

Business Wire

2 years ago

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease

Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets

Business Wire

2 years ago

Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds

Business Wire

2 years ago

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds

GlobeNewswire

2 years ago

CORRECTION – Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)

Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property

Business Wire

2 years ago

Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders

Business Wire

2 years ago

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders

Mullen Opens Dominican Republic and Caribbean Markets for Commercial EVs

GlobeNewswire

2 years ago

Mullen Opens Dominican Republic and Caribbean Markets for Commercial EVs

Has Optex Systems Holdings, Inc's (NASDAQ:OPXS) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Simply Wall St.

2 years ago

Has Optex Systems Holdings, Inc's (NASDAQ:OPXS) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Business Wire

2 years ago

Cherry Hill Mortgage Investment Corporation Announces Taxable Composition of 2023 Dividends

J.V.B. Financial Group, LLC Hires George Holstead to Expand Middle Markets Group

GlobeNewswire

2 years ago

J.V.B. Financial Group, LLC Hires George Holstead to Expand Middle Markets Group

Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split

GlobeNewswire

2 years ago

Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split

Energous Announces Change of Chief Financial Officer

Business Wire

2 years ago

Energous Announces Change of Chief Financial Officer

SYLA Technologies Became the Largest Shareholder of RIBERESUTE by Acquiring 20.39% of its Shares

GlobeNewswire

2 years ago

SYLA Technologies Became the Largest Shareholder of RIBERESUTE by Acquiring 20.39% of its Shares

Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting

GlobeNewswire

2 years ago

Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting

Banzai Unveils 2024 Webinar Insights Guide: The Must-Have Resource for Marketers Seeking Successful Webinar Strategies

GlobeNewswire

2 years ago

Banzai Unveils 2024 Webinar Insights Guide: The Must-Have Resource for Marketers Seeking Successful Webinar Strategies

17EdTech Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement

GlobeNewswire

2 years ago

17EdTech Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement

Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States

Business Wire

2 years ago

Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States

Fossil Taps Tangiblee for ‘First of Its Kind’ Virtual Try-on Experience

WWD

2 years ago

Fossil Taps Tangiblee for ‘First of Its Kind’ Virtual Try-on Experience

SYLA Technologies Appoints Takuya Hanada as Chief Financial Officer

GlobeNewswire

2 years ago

SYLA Technologies Appoints Takuya Hanada as Chief Financial Officer

Better Therapeutics Insiders Added US$6.57m Of Stock To Their Holdings

Simply Wall St.

2 years ago

Better Therapeutics Insiders Added US$6.57m Of Stock To Their Holdings

Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series

Business Wire

2 years ago

Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series

Exela Technologies Announces Adjournment of Annual Meeting until January 26, 2024

GlobeNewswire

2 years ago

Exela Technologies Announces Adjournment of Annual Meeting until January 26, 2024

Business Wire

2 years ago

Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market

Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series

Business Wire

2 years ago

Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series

Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373

Business Wire

2 years ago

Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373

Analysts Say 3 Stocks Have a Combined Upside of 3000%

InvestorPlace

2 years ago

Analysts Say 3 Stocks Have a Combined Upside of 3000%

Exela Technologies Reminds Stockholders to Cast Their Vote for Upcoming Annual Meeting of Stockholders to be held on December 29, 2023 at 10:00 a.m. Eastern Time

GlobeNewswire

2 years ago

Exela Technologies Reminds Stockholders to Cast Their Vote for Upcoming Annual Meeting of Stockholders to be held on December 29, 2023 at 10:00 a.m. Eastern Time

United Nations High Commissioner for Refugees Awards Polar Power Initial Contract to Assure Uninterrupted Quality Electric Power for African Offices

GlobeNewswire

2 years ago

United Nations High Commissioner for Refugees Awards Polar Power Initial Contract to Assure Uninterrupted Quality Electric Power for African Offices

Enveric Biosciences to Participate in Biotech Showcase 2024 During "J.P. Morgan Week 2024"

Business Wire

2 years ago

Enveric Biosciences to Participate in Biotech Showcase 2024 During "J.P. Morgan Week 2024"

Business Wire

2 years ago

Cherry Hill Mortgage Investment Corporation Authorizes Preferred Stock Repurchase Program

EMCORE Corporation (NASDAQ:EMKR) Shares Could Be 48% Below Their Intrinsic Value Estimate

Simply Wall St.

2 years ago

EMCORE Corporation (NASDAQ:EMKR) Shares Could Be 48% Below Their Intrinsic Value Estimate

Business Wire

2 years ago

Cherry Hill Mortgage Investment Corporation Announces Common and Preferred Dividends for the Fourth Quarter 2023

Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds

Business Wire

2 years ago

Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds

Fusion Fuel Green Hosts Third Quarter 2023 Investor Update

GlobeNewswire

2 years ago

Fusion Fuel Green Hosts Third Quarter 2023 Investor Update

Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives

Business Wire

2 years ago

Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives

11 Cheapest Stocks With Biggest Upside

Insider Monkey

2 years ago

11 Cheapest Stocks With Biggest Upside

Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry

Business Wire

2 years ago

Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry

7 Under-$10 Names to Put in Your Christmas Stocking

InvestorPlace

2 years ago

7 Under-$10 Names to Put in Your Christmas Stocking

Share on Social Networks: